Avantax Planning Partners, Inc. Atara Biotherapeutics, Inc. Transaction History

Avantax Planning Partners, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$30.9 - $42.97 $4,665 - $6,488	-151 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$35.05 - $43.5 $5,292 - $6,568	151 New	151 $6,000
Q2 2018 Aug 13, 2018	SELL	$35.15 - $51.45 $6,959 - $10,187	-198 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$18.0 - $48.35 $3,564 - $9,573	198 New	198 $8,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.34B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Avantax Planning Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Avantax Planning Partners, Inc. with notifications on news.